Business
Guardant Health to Present Data Highlighting Advances in Multi-Cancer Detection and Liquid and Tissue Molecular Profiling at AACR
Four oral sessions to be presented, including validation data for Shield MCD test, selected for highly anticipated NCI Vanguard Study 18 total abstracts to
About this update from Guardant Health, Inc.
[{"type":"text","content":"\n\nFour oral sessions to be presented, including validation data for Shield MCD test, selected for highly anticipated NCI Vanguard Study\n\n\n18 total abstracts to showcase significant developments in multiomic profiling with liquid and tissue biopsies across screening, recurrence monitoring and treatment selection\n\n\n PALO ALTO, Calif.--(BUSINESS WIRE)--\nGuardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will present 18 abstracts, including four oral sessions, showcasing advances in multi-cancer detection and multiomic precision oncology testing enabled by its Guardant Infinity™ smart liquid biopsy platform at the 2025 American Association for Cancer Research (AACR) Annual Meeting, April 25-30 in Chicago.\n\nKey data that will be highlighted include:\n\n\nAn oral presentation of performance data for the Shield™ MCD test, selected for the National Cancer Institute’s Vanguard Study evaluating emerging multi-cancer detection (MCD) technology\n\n\nAdditional oral presentations on methylation-based cancer signal of origin identification, methylation profiling for lung cancer subtyping, and a real-world data analysis of BRAF mutations in non-small cell lung cancer\n\n\nAnalytical validation of Guardant’s new tissue profiling assay with integrated multiomics, showing a high success rate with minimal tissue input and supporting the acceleration of novel biomarker discovery\n\n\nNew methylation-based applications for liquid biopsy, including molecular subtyping of lung and breast cancer, rule-out of actionable genomic mutations, and identification of promoter methylation and MTAP deletions\n\n\n“We look forward to sharing new data demonstrating the tremendous potential of the Guardant Infinity smart liquid biopsy platform to provide researchers and healthcare providers with a more complete picture of cancer, including genomics, epigenomics and more,” said Helmy Eltoukhy, Guardant Health chairman and co-CEO. “This multidimensional view of cancer biology is enabling advances in precision oncology ranging from blood-based multi-cancer detection to identification of novel biomarkers that can help bring the next generation of cancer therapeutics to patients sooner.”\n\nThe full abstracts for Guardant Health and a list of all abstracts being presented at AACR 2025 can be found on the AACR website....